The Effect of Metformin Use on Mortality of COVID-19 Patients with Diabetes Mellitus
DOI:
https://doi.org/10.26911/jepublichealth.2022.07.02.07Abstract
Background: COVID-19 is a disease caused by infection with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 is still a worldwide threat because of its high morbidity and mortality. This is influenced by the occurrence of hypertension, obesity, age and diabetes mellitus. However, currently there is still controversy in the results of research regarding the use of metformin in COVID-19 with type 2 diabetes mellitus (type 2 DM). This study was aimed to analyze the effect of metformin in COVID-19 patients with diabetes mellitus on mortality rates.
Subjects and Method: This study was a systematic review and meta-analysis with the following PICO. P: COVID-19 patient with type-2 diabetes mellitus. I: administration of metformin therapy. C: therapy other than metformin and O: mortality. The articles used in this study were obtained from several databases, namely PubMed, Science Direct, Proquest, SpringerLink, Google Scholar and Scopus. The article search keywords were: “COVID-19” OR “coronavirus” AND “diabetes” AND “metformin” AND “mortality.” Articles included are full-text English using a cohort study design from 2020 to 2021 and reporting the Odds Ratio in multivariate analysis. The selection of articles was carried out using the PRISMA flow chart. The articles were analyzed using the Review Manager 5.3 application.
Results: A total of 7 cohort studies involving 136,321 COVID-19 patients from the Americas (USA and Alabama United States), Europe (France and Spain), and Asia (China and South Korea) were selected for systematic review and meta-analysis. The data collected showed that COVID-19 patients with diabetes mellitus who were given metformin reduced the risk of death by 0.90 times higher compared to COVID-19 patients with diabetes mellitus who were not given metformin therapy (aOR= 0.90; CI 95%= 0.68 to 1.19; p=0.450).
Conclusion: Metformin can reduce the risk of death in COVID-19 patients with diabetes mellitus.
Keywords: Diabetes, COVID-19, SARS-CoV-2, metformin, mortality
Correspondence:
Dwi Trisnawati Zainal. Masters Program of Public Health Science, Universitas Sebelas Maret. Jl. Ir. Sutami 36A Surakarta 57126, Central Java. Email: dwitrisnawatiz@gmail.com. Mobile: +62-8133-1282-009.
References
Baker C, Retzik-Stahr C, Singh V, Plomon-don R, Anderson V, Rasouli N (2021). Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 12: 1–13. doi: 10.1177/20420188-20980225.
Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronsk, J, McNeil C, et al. (2021). Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. The Lancet Heal-thy Longevity. 2(1): e34–e41. doi: 10.-1016/S2666-7568(20)30033-7.
Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, et al. (2016). Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 119(5): 652–665. doi: 10.1161/circresaha.116.308445.
Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-salameh A (2021). Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. 2020, 1500–1515. Diabetologia. 63:1500-1515. doi: 10.1007/s00125-020-05180-x.
CASP (2018). Critical appraisal skills program cohort study checklist. Retrieved from https://caspuk.net/wp-content/uploads/2018/01/CASP_Cohort-Study-Checklist_2018.pdf.
Cho NH (2017). Eighth Edition 2017. In IDF Diabetes Atlas, 8th edition. https://www.idf.org/aboutdiabetes/type-2-diabetes.html.
Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A (2021). Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Frontiers in Endocrinology. 11: 1081. doi: 10.3389/FENDO.2020.600439/BIBTE.
WHO (2022). WHO Coronavirus (COVID-19) Dashboard. Retrieved February 10, 2022 from https://www.who.int/data#dashboards.
Hasan SS, Kow CS, Bain A, Kavanagh S, Merchant HA, Hadi MA (2021). Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert Opin Pharmacother. 22(2): 229–240. doi: 10.1080/14656566.2020.1837114.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181(2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052.
Hu B, Guo H, Zhou P, Shi ZL (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 19(3): 141–154. doi: 10.1038/s41-579-020-00459-7.
Huang I, Lim MA, Pranata R (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression. Diabetes Metab. 14(4): 395. doi: 10.1016/J.DSX.2020-.04.018.
Kerner W, Brückel J, German Diabetes As-sociation (2014). Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol. Diabetes. 122(07): 384–386 doi.org: 10.1055/s0034-1366278.
Lalau J, Al-salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, Allix I, et al. (2020). Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 47: 1262-3636 doi: 10.1016/j.diabet.2020.101216.
Luo P, Qiu L, Liu Y, Liu XL, Zheng JL, Xue HY, Liu WH, et al. (2020). Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. American J Trop Med Hyg. 103(1): 69–72. doi: 10.4269/ajtmh.200375.
Oduro-Mensah E, Tetteh J, Adomako I, Ad-jei-Mensah E, Owoo C, Yawson A O, Oliver-Commey JA, et al. (2020). Clinical features of COVID-19 in Ghana: Symptomatology, illness severity and comorbid non-communicable diseases. Ghana Med J. 54(4): 23–32. doi: 10.4314/GMJ.V54I4S.5.
Oh TK, Song IA (2021). Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta Diabetol. 58(6): 771–778. doi: 10.1007/s00592-020-01666-7.
Pérez-Belmonte LM, Torres-Peña JD, Ló-pez-Carmona MD, Ayala-Gutiérrez MM, Fuentes-Jiménez F, Huerta LJ, Muñoz JA, et al. (2020). Mortality and other adverse outcomes in patients with type 2 diabetes mellitus ad-mitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med 18(1). doi: 10.1186/s12916-020-01832-2.
Poly TN, Islam MM, Li Y, Lin MC, Hsu MH, Wang YC (2021). Metformin use is associated with decreased mortality in COVID-19 patients with diabetes: evidence from retrospective studies and biological mechanism. J Clin. Med. 10(16). doi: 10.3390/jcm1-0163507.
Singh AK, Singh R (2020). Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Res Clin Pract, 165 (January). doi: 10.1016/j.diabres.2020.108268.
Wargny M, Potier L, Gourdy P, Pichelin M, Amadou C, Benhamou PY, Bonnet JB, et al. (2021). Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia. 64(4): 778–794. doi: 10.1007/S0012-5-020-05351-W.
Yang W, Sun X, Zhang J, Zhang KZ (2021). The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. Elsevier. 178 (108977). doi: 10.1016/j.diabres.2021.108977.
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M (2020). Reducing mortality from 2019-nCoV: host-directed therapies should be an option. The Lancet. 395(10224): e35–e36. doi: 10.1016/S0140-6736(20)30305-6.
